spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

Digital Medicine & Medtech Showcase 2019

Digital Medicine & Medtech Showcase 2019

8-9 January 2019
Parc 55 San Francisco - a Hilton Hotel

The Digital Medicine and Medtech Showcase is the dedicated home for the digital health and medtech communities during Biotech Showcase™ and one
of the healthcare industry’s biggest weeks. Taking place January 8–9, Digital Medicine & Medtech Showcase includes two days of networking opportunities, curated presentations and specialized sessions.

These program elements create a forum for innovative digital medicine and medtech companies to plan for successful partnerships and evaluate growth prospects in a shifting healthcare market. Attendees are able to schedule one-to-one meetings using partneringONE® and have full access to the concurrent event, Biotech Showcase.

Speakers: https://ebdgroup.knect365.com/digimed-showcase/speakers

Program: https://ebdgroup.knect365.com/digimed-showcase/agenda/1

phone +1 760 930 0500
email conferences@ebdgroup.com
web https://bit.ly/2RYbdAB
email San Francisco, CA
 
Print this page
Send to a friend
   
spacer
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

White Papers

7 Common Myths about QP Training Debunked: A Guide for Senior Managers

RSSL

The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
More info >>


News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement